Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer

Exclusion Criteria

• •Diagnosis of other malignancies within 5 years prior to the first dose (excluding adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or carcinoma in situ that has undergone radical resection).
• •Current participation in an interventional clinical study or receipt of other investigational drugs or devices within 4 weeks prior to the first dose.
• •Prior treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, or drugs targeting other stimulatory or co-inhibitory T-cell receptors .
• •Systemic treatment with Chinese herbal medicines with antitumor indications or immunomodulatory agents (e.g., thymosin, interferon, interleukin, excluding local use for pleural effusion control) within 2 weeks prior to the first dose.
• •Active autoimmune disease requiring systemic treatment (e.g., disease-modifying agents, glucocorticoids, or immunosuppressants) within 2 years prior to the first dose. Replacement therapies (e.g., thyroxine, insulin, or physiologic glucocorticoids for adrenal/pituitary insufficiency) are not considered systemic treatment.
• •Systemic glucocorticoid therapy (excluding nasal sprays, inhalations, or other local routes) or any immunosuppressive therapy within 7 days prior to the first dose.
• •History of allogeneic organ transplantation (excluding corneal transplants) or allogeneic hematopoietic stem cell transplantation.
• •Known hypersensitivity to any study drug.
• •Presence of multiple factors affecting cisplatin use (e.g., platinum allergy).
• •Inadequate recovery from prior intervention-related toxicity or complications (i.e., \>Grade 1 or not returned to baseline, excluding fatigue or alopecia).
• •Known history of Human Immunodeficiency Virus（ HIV） infection .
• •Untreated active hepatitis B （HBV）(defined as HBsAg-positive with HBV-DNA exceeding the upper limit of normal at the study site).
• •Active hepatitisC (HCV) infection (HCV antibody-positive with HCV-RNA above the lower detection limit).
• •Administration of live vaccines within 30 days prior to the first dose (Cycle 1, Day 1).
• •Pregnant or lactating women.
• •Severe or uncontrolled systemic diseases, including:Symptomatic resting Electrocardiograph abnormalities (e.g., complete left bundle branch block, ≥Grade II heart block, ventricular arrhythmia, atrial fibrillation).Unstable angina, congestive heart failure, or chronic heart failure ≥NYHA class II.Arterial thromboembolism, ischemia, myocardial infarction, unstable angina, stroke, or transient ischemic attack within 6 months prior to enrollment.Poorly controlled hypertension (systolic \>140 mmHg, diastolic \>90 mmHg).History of non-infectious pneumonitis requiring glucocorticoids within 1 year or current active interstitial lung disease.
• •Active tuberculosis.
• •Active or uncontrolled infection requiring systemic therapy.
• •Clinically active diverticulitis, abdominal abscess, or gastrointestinal obstruction.
• •Liver diseases (e.g., cirrhosis, decompensated liver disease, acute/chronic active hepatitis).
• •Poorly controlled diabetes (fasting blood glucose \>10 mmol/L).
• •Urine protein ≥++ on urinalysis with 24-hour urine protein \>1.0 g.
• •Psychiatric disorders impairing compliance.
• •Any condition (e.g., medical history, abnormal lab/test results, concurrent treatments) that may interfere with study outcomes, participation, or pose risks, as judged by the investigator.